Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Apellis Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1—Newly Registered Securities
| Security Type | Security Class Title |
Fee Calculation Rule |
Amount Registered (1) |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee | |||||||
| Equity | Common Stock, $0.0001 par value per share | Other | 4,619,409 (2) | $51.82 (3) | $239,377,775 (3) | 0.00011020 | $26,379.44 | |||||||
| Total Offering Amounts | $239,377,775 | $26,379.44 | ||||||||||||
| Total Fee Offsets | — | |||||||||||||
| Net Fee Due | $26,379.44 | |||||||||||||
| (1) | In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
| (2) | Consists of (i) 4,219,409 shares issuable under the 2017 Stock Incentive Plan and (ii) 400,000 shares issuable under the 2020 Inducement Stock Incentive Plan. |
| (3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant’s Common Stock as reported on the Nasdaq Global Select Market on February 14, 2023. |